CRISPR Therapeutics AG (BKK:CRSP03)
Thailand
· Delayed Price · Currency is THB | Market Cap | 158.97B |
| Revenue (ttm) | 110.69M |
| Net Income (ttm) | -18.34B |
| Shares Out | n/a |
| EPS (ttm) | -204.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,052 |
| Average Volume | 22,513 |
| Open | 3.580 |
| Previous Close | 3.600 |
| Day's Range | 3.200 - 3.580 |
| 52-Week Range | 2.920 - 3.880 |
| Beta | n/a |
| RSI | 45.33 |
| Earnings Date | May 11, 2026 |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve... [Read more]
Financial Performance
In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.
Financial numbers in USDNews
CRISPR Therapeutics AG Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is rapidly expanding its pipeline beyond Casgevy, with six programs set for near-term data and a focus on cardiovascular, autoimmune, and oncology franchises. Innovations in gene editing, delivery, and siRNA are driving new therapies, while strong financials support broad R&D investment.
Wall Street Is Completely Wrong About These 5 Stocks
Steven Orr, Founder & CEO, Quasar Markets breaks down the five stocks Wall Street is mispricing and explains how he's finding real opportunities across AI, biotech, crypto and consumer right now.
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Vi...
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its conv...
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other fac...
CRISPR Therapeutics AG Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a strategic shift toward disease-focused franchises in cardiovascular and autoimmune areas, with robust pipeline progress expected by 2027. Casgevy momentum continues, while in vivo, siRNA, and cell therapy programs advance, supported by strong early data and upcoming clinical milestones.
CRISPR Therapeutics AG Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
Zugo-cel, an allogeneic CAR-T with advanced edits, is advancing in both oncology and autoimmune indications, showing strong early efficacy and broad applicability. Regulatory and commercialization strategies focus on parallel development, competitive pricing, and global access, while in vivo CAR-T platforms are being engineered for future expansion.
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
Casgevy, the company's gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in fourth-quarter revenue and $116 million for the full year.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we ...
CRISPR Therapeutics AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Multiple franchises are advancing with strong commercial and clinical momentum, including Casgevy’s global rollout, best-in-class in vivo gene editing, and promising CAR-T and cardiovascular programs. Key data readouts and regulatory clarity in 2026 are expected to drive the next phase of growth.
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading ge...
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the definitive coming-out party for the genomic revolution.
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer
CRISPR Therapeutics AG (NASDAQ: CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel, formerly CTX112), its investigational allogeneic CAR T targeting CD19, in development for autoimmu...
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 ...
CRISPR Therapeutics AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Significant progress across the portfolio includes strong CASGEVY launch, promising CTX310 and Factor XI data, and upcoming cell therapy updates. Differentiation in gene editing safety and lipid management, plus strategic positioning in competitive markets, support a positive outlook.
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Med...
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising hop...
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ci...
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile-
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
CRISPR Therapeutics AG Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A diversified pipeline in cardiovascular, autoimmune, oncology, and diabetes is advancing, with key clinical readouts expected in the next year. CASGEVY's launch is progressing well, supported by strong demand and expanding site productivity. Regulatory and partnership strategies are evolving, with major data and policy developments anticipated in the coming months.
CRISPR Therapeutics AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference
CASGEVY's launch is progressing well, with expansion into multiple therapeutic areas and a strong cash position supporting strategic growth. Durable, one-time therapies in cardiovascular and other indications are prioritized, with siRNA and gene editing platforms advancing toward key clinical milestones.